Key Takeaways
- Huntsville’s Serina Therapeutics has raised $10 million for clinical trials focused on Parkinson’s treatment.
- The funding from JuvVentures will support the development of an innovative drug-delivery system.
- The system combines Serina’s technology with a wearable device to enhance the effectiveness of apomorphine.
Funding and Clinical Trials Initiation
Serina Therapeutics, a biotechnology firm located at the HudsonAlpha Institute of Biotechnology in Huntsville, has successfully secured $10 million in funding aimed at advancing clinical trials for a novel medication delivery system targeting advanced Parkinson’s disease. The company announced its plans to initiate trials in the latter half of this year.
The financial backing has been provided by JuvVentures, an investor based in the UK. Serina Therapeutics intends to utilize this funding to enhance the delivery of apomorphine, an existing Parkinson’s treatment that has shown potential in managing symptoms of the disease. By leveraging its proprietary drug-delivery technology, the company aims to improve the medication’s effectiveness and user-friendliness.
A significant aspect of this new treatment involves the integration of a wearable device developed by Enable Injections. This device is designed to facilitate the administration of apomorphine, potentially allowing for more sustained effects within the body. The innovative approach proposed by Serina Therapeutics could represent a pivotal advancement in how Parkinson’s disease medications are delivered and managed, aiming to improve the quality of life for patients who face challenges with traditional treatment methods.
As the company looks forward to commencing clinical trials later this year, the implications of this research could transform therapeutic practices in the treatment of Parkinson’s disease. The advancement not only showcases Serina’s commitment to addressing critical healthcare needs but also signifies a collaborative effort with technology partners to enhance patient outcomes. The results of these trials will be closely monitored by the medical community and patients alike, eager for effective solutions to long-standing treatment challenges in Parkinson’s care.
The content above is a summary. For more details, see the source article.